Lukas Roell

University of Melbourne
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (33)

Year:

2026

Year:

2026

According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms, particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and may contribute to P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P3b subcomponent amplitudes and latencies, cognition, and symptom severity in SSD. In total, 107 patients and 107 healthy controls (HC) were included in the study, with the exact numbers varying across specific analyses. We grouped patients into higher (SSD+, N = 41) and lower (SSD−, N = 65) symptom severity clusters based on PANSS total scores. P3b amplitudes were lower in SSD patients than HC at central and parietal sites. SSD+ exhibited widespread P3b amplitude reductions, significant at parietal and trend-level at central and frontal regions, while SSD− showed a trend-level amplitude reduction limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P3b amplitudes at central and parietal sites within SSD− and overall SSD group. Although P3b amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P3b associations. Our findings suggest P3b amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher illness severity, and that enhanced lDLPFC GABA may contribute to offsetting these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns associated with cognitive dysfunction in SSD.

Year:

2026

Year:

2026

Year:

2026

When the brain and body misalign, emotional experience and sense of reality can be disrupted. Although such atypical experiences are central to schizophrenia spectrum disorders (SSD), interoception, processing of internal bodily signals, remains poorly understood in individuals with SSD, particularly across subjective, behavioural, and neural domains. We tested whether SSD is associated with convergent alterations across interoceptive domains and whether these relate to clinical symptoms in a cross-sectional observational design. Patients with SSD ( n = 53) and matched healthy controls (HC; n = 60) completed an EEG experiment comprising eyes-closed and eyes-open resting-state recordings and a heartbeat counting task (HCT), followed by self-report measures. Interoceptive accuracy was derived from the HCT, while cortical responses to afferent cardiac signals were indexed by heartbeat evoked potentials (HEP). In individuals with SSD, subjective interoceptive awareness was altered, characterised by impaired regulation and negative bodily appraisal, alongside elevated depersonalization. At the behavioral level, interoceptive accuracy was marginally lower. HEP positivity was attenuated, most clearly during HCT and, to a lesser extent, in eyes-open rest, over centro-parietal regions, consistent with context-dependent alterations in cortical processing of afferent bodily signals. Symptom–interoception links were largely modest, with depersonalization emerging as the most consistent correlate of clinical severity, suggesting that interoceptive disturbances in SSD may reflect a trait-like, disorder-central alteration. Together, these findings indicate that SSD involves pervasive disturbances in bodily self-experience, marked by impaired interoceptive regulation and by context-dependent neural attenuation during interoceptive engagement. This profile highlights interoceptive dysfunction as a disorder-central feature with potential prognostic and therapeutic relevance.

Year:

2026

Schizophrenia spectrum disorders (SSDs) are clinically and biologically heterogeneous and lack reliable biomarkers for stratification and outcome prediction. Evidence from postmortem, fluid biomarker, and neuroimaging studies suggests that blood–brain barrier (BBB) dysfunction may contribute to pathophysiology in a biologically defined subgroup. However, findings are inconsistent and often based on cross-sectional or indirect measures. The IMPACT study is a longitudinal, multimodal investigation designed to quantify BBB permeability across disease phases using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to integrate these measures with deep clinical phenotyping. We recruit inpatients with SSDs and healthy controls (HC). Participants undergo multimodal MRI including DCE-MRI at three time points: acute psychosis (baseline; V1), early treatment (4-6 weeks; V2), and long-term follow-up (2.5 years; V3). Clinical characterization includes standardized measures of psychopathology, functioning and cognition. Blood samples are collected at each visit, while CSF is obtained only when clinically indicated in the SSD group. DCE-MRI-derived voxelwise permeability metrics are then analyzed. Primary objectives are to (i) compare BBB leakage cross-sectionally between SSD and HC and (ii) characterize spatial and temporal leakage profiles across illness phases. Secondary objectives include analyzing associations with psychopathology and biological (e.g., inflammatory) signatures, as well as exploratory identification of subgroups. By providing a longitudinal, BBB-specific neuroimaging framework embedded in a deep phenotyping infrastructure, IMPACT aims to elucidate BBB alterations in SSDs and to support biologically informed stratification approaches in precision psychiatry.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (32)

Enrico Schulz

Principle Investigator

Ludwig-Maximilians-Universität München

GERMANY
View details

Daniel Keeser

RG Neuromodulation And Multimodal Neuroimaging, RG Clinical Deep Phenotyping (CDP)

Ludwig-Maximilians-Universität München

GERMANY
View details

Andrea Schmitt

Klinikum der Universität München

GERMANY
View details

Eva C. Schulte

Professor of Psychiatric Genomics, Division Head

Technical University of Munich

GERMANY
View details

Brenda WJH Penninx

Professor

-

NETHERLANDS
View details

Zhuanghua Shi

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Sergi Papiol

University Hospital, LMU Munich

GERMANY
View details

Astrid Roeh

University Hospital Augsburg

GERMANY
View details

Florian Raabe

Group Leader & Deputy Chief Physician

Max Planck Institute of Psychiatry

GERMANY
View details

Joseph Firth

The University of Manchester

UNITED KINGDOM
View details

Tonatiuh Pena Centeno

Head of bioinformatics core unit

German Center for Neurodegenerative Diseases

GERMANY
View details

Kerry Ressler

Emory University

UNITED STATES
View details

Michael Gaebler

Group leader

Max Planck Institute for Human Cognitive and Brain Sciences

GERMANY
View details

EWA BALKOWIEC-ISKRA

Professor

Medical University of Warsaw

POLAND
View details

Thomas G Schulze

Clinical Professor

SUNY Upstate Medical University

UNITED STATES
View details

Keith Smith

University Of Strathclyde

UNITED KINGDOM
View details

Lalit Kaurani

Group Leader

Institute of Physiology of the Czech Academy of Sciences

CZECH REPUBLIC
View details

Urs Heilbronner

Research Associate (tenured)

University Hospital, LMU Munich

GERMANY
View details

Til Ole Bergmann

Associate Professor

Johannes Gutenberg Universität Mainz

GERMANY
View details

Madhur Mangalam

Assistant Professor

University of Nebraska - Lincoln

UNITED STATES
View details

Udo Dannlowski

University of Münster

GERMANY
View details

Nicola Warren

University of Queensland

AUSTRALIA
View details

Isabel Maurus

University Hospital

GERMANY
View details

Tilo Kircher

Professor, Chair

University of Marburg

GERMANY
View details

Frank Padberg

Professor of Psychiatry and Psychotherapy

Ludwig-Maximilians-Universität München

GERMANY
View details

Martien Kas

Scientific Staff, Professor

Rijksuniversiteit Groningen

NETHERLANDS
View details

Sophia Stoecklein

LMU University Hospital

GERMANY
View details

Dan Siskind

Professor

University of Queensland

AUSTRALIA
View details

James Cole

Associate Professor in Neuroimage Analysis

University College London

UNITED KINGDOM
View details

Eva Reininghaus

Univ. Prof. PD, MD, MBA

Medical University of Graz

AUSTRIA
View details

Michaela V. Bonfert

Ludwig-Maximilians-Universität München

GERMANY
View details

Peter Falkai

Chair

Ludwig-Maximilians-Universität München

GERMANY
View details